Información de Supernus Pharmaceuticals Inc, dividendo de Supernus Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Supernus Pharmaceuticals Inc Compañía

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Información de Supernus Pharmaceuticals Inc



Símbolo de cotizaciónSUPN

Nombre de la empresaSupernus Pharmaceuticals Inc

Fecha de salida a bolsaDec 28, 2010

Director ejecutivoKhattar (Jack A)

Número de empleados674

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 28

Dirección9715 Key West Avenue

CiudadROCKVILLE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal20850

Teléfono13018382500

Sitio Webhttps://www.supernus.com

Símbolo de cotizaciónSUPN

Fecha de salida a bolsaDec 28, 2010

Director ejecutivoKhattar (Jack A)

Ejecutivos de Supernus Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.20M

-2.16%

Mr. Frederick M. Hudson, CPA

Independent Director

60.41K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

27.28K

--

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

27.05K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

18.44K

+3.11%

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

17.04K

+4.32%

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

13.34K

+4.61%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

8.23K

+8.95%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Mr. Peter Vozzo

Investor Relations

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.20M

-2.16%

Mr. Frederick M. Hudson, CPA

Independent Director

60.41K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

27.28K

--

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

27.05K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

18.44K

+3.11%

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

17.04K

+4.32%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Net product sales-Qelbree

304.65M

42.37%

Net product sales - GOCOVRI

146.82M

20.42%

Collaboration revenue

53.00M

7.37%

Net product sales-APOKYN

47.77M

6.64%

Net product sales- Trokendi XR

42.42M

5.90%

Otro

124.29M

17.29%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

718.95M

100.00%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Net product sales-Qelbree

304.65M

42.37%

Net product sales - GOCOVRI

146.82M

20.42%

Collaboration revenue

53.00M

7.37%

Net product sales-APOKYN

47.77M

6.64%

Net product sales- Trokendi XR

42.42M

5.90%

Otro

124.29M

17.29%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.47%

Millennium Management LLC

5.65%

Vanguard Portfolio Management, LLC

5.58%

Armistice Capital LLC

4.76%

Vanguard Capital Management, LLC

4.25%

Otro

66.28%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.47%

Millennium Management LLC

5.65%

Vanguard Portfolio Management, LLC

5.58%

Armistice Capital LLC

4.76%

Vanguard Capital Management, LLC

4.25%

Otro

66.28%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

48.46%

Investment Advisor/Hedge Fund

26.81%

Hedge Fund

21.60%

Individual Investor

4.46%

Research Firm

2.83%

Pension Fund

1.54%

Venture Capital

1.40%

Bank and Trust

0.64%

Sovereign Wealth Fund

0.21%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

651

66.06M

113.82%

+238.90K

2025Q4

613

59.41M

103.62%

-4.43M

2025Q3

575

60.19M

104.97%

-3.36M

2025Q2

565

63.61M

113.46%

-2.51M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

7.82M

13.58%

+177.82K

+2.33%

Dec 31, 2025

Millennium Management LLC

3.28M

5.7%

+245.49K

+8.09%

Feb 11, 2026

Armistice Capital LLC

2.76M

4.8%

-72.00K

-2.54%

Dec 31, 2025

Nomura Investment Management Business Trust

2.31M

4.01%

-223.90K

-8.84%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

2.71M

4.71%

-289.60K

-9.65%

Dec 31, 2025

Point72 Asset Management, L.P.

2.26M

3.93%

+503.32K

+28.57%

Dec 31, 2025

State Street Investment Management (US)

2.22M

3.85%

+31.67K

+1.45%

Dec 31, 2025

Khattar (Jack A)

2.25M

3.9%

+34.57K

+1.56%

Mar 13, 2026

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

AdvisorShares Psychedelics ETF

7.48%

iShares Neuroscience and Healthcare ETF

3.83%

Invesco Pharmaceuticals ETF

3.32%

State Street SPDR S&P Pharmaceuticals ETF

3.11%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.21%

Invesco S&P SmallCap Health Care ETF

1.89%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.63%

Lattice Hartford Multifactor Small Cap ETF

1.3%

iShares U.S. Pharmaceuticals ETF

1.14%

First Trust Multi-Manager Small Cap Opportunities ETF

0.68%

AdvisorShares Psychedelics ETF

Proporción7.48%

iShares Neuroscience and Healthcare ETF

Proporción3.83%

Invesco Pharmaceuticals ETF

Proporción3.32%

State Street SPDR S&P Pharmaceuticals ETF

Proporción3.11%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción2.21%

Invesco S&P SmallCap Health Care ETF

Proporción1.89%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.63%

Lattice Hartford Multifactor Small Cap ETF

Proporción1.3%

iShares U.S. Pharmaceuticals ETF

Proporción1.14%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción0.68%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos